TrialAntimicrobial agents and chemotherapy2022

Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.

Run Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.